Unicycive(US:UNCY) Prnewswire·2025-09-24 15:30Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [2][4]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is a company listed on NASDAQ under the ticker UNCY [2]. - The firm Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations and Stock Performance - The complaint against Unicycive alleges that the company and its executives made false or misleading statements regarding their readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of their OLC NDA [4]. - Following a press release on June 10, 2025, regarding FDA deficiencies, Unicycive's stock price dropped by $3.68 per share, a decline of 40.89%, closing at $5.32 per share [5]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock fell by $2.03 per share, or 29.85%, closing at $4.77 per share [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 between March 29, 2024, and June 27, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to direct and oversee the litigation [7].